Abstract 553P
Background
Colorectal cancer (CRC) is a common and lethal malignancy which is related to aging, with almost 40% of CRC diagnosed above 75 years in both Australia and the United States. Adjuvant chemotherapy is a key treatment in patients with Stage III colorectal cancer, and combination chemotherapy using a fluoropyrimidine and oxaliplatin doublet (such as FOLFOX or XELOX) is the current standard of care, with a 20% reduction in risk of death compared to fluoropyrimidine monotherapy. It is not clear if this benefit is seen in elderly patients in the community setting.
Methods
TNM stage, chemotherapy treatment records, and overall survival data was obtained for 2923 patients with stage III colorectal cancer by linkage of New South Wales cancer registry records with data from the births, deaths and marriages registry. To determine the impact of age, two separate cox proportional hazard models were used to compare the effect of combination chemotherapy regimens on overall survival (OS) for patients 70 and older, and younger than 70. Multivariate analysis was performed using a subset of 1008 patients with more complete clinicopathologic data.
Results
Patients in the 70yrs and older age group had poorer OS (5yr OS 58.8 vs 76.7%, HR 0.47 95%CI 0.41 – 0.54, p
Conclusions
Patients 70 years and older, with stage III colorectal, may gain a similar OS benefit with adjuvant oxaliplatin doublet chemotherapy as younger patients. Combination adjuvant chemotherapy should be considered in elderly patients
Clinical trial identification
Legal entity responsible for the study
The Centre for Oncology Education and Research Translation (CONCERT)
Funding
The Centre for Oncology Education and Research Translation (CONCERT)
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract